Sarah Stoiber
Partner
Sarah Stoiber is a partner in Goodwin’s Technology and Life Sciences group and a member of the firm’s Strategic Technology Transactions and Licensing practice. She joined Goodwin in 2016 and represents public and private companies in all stages of maturity in the technology and life sciences industries in in connection with their commercial, M&A, royalty monetization, acquisitions and financings, and intellectual property transactions, including complex strategic collaboration, co-development, licensing and partnering transactions.
Representative Matters
- Nanobiotix in its co-development and commercialization agreement with Janssen for a potential first-in-class radioenhancer; upfront value of up to $60 million plus up to $1.8 billion in success payments, additional amounts for additional indications and double-digit royalties on sales of the compound
- LifeEdit Therapeutics in its multi-target collaboration to discover and develop gene editing therapies for rare and cardiometabolic diseases, with LifeEdit receiving an upfront cash payment and milestone payments of $250-335 million for each of seven development programs, as well as tiered royalties on global net sales
- HIBio in its equity participation agreement and license agreements with MorphoSys to develop and commercialize MorphoSys’ felzartamab, and MOR210
- Allogene in forming a first-of-its kind joint venture with Overland Pharmaceuticals (a Hillhouse affiliate) to develop and commercialize allogeneic CAR-T to patients in Greater China and certain South East Asian countries and Overland’s $117 Million investment in the JV and Allogene’s licensing to the JV
- BridGene Biosciences in its strategic research collaboration and licensing agreement with Takeda, using BridGene’s proprietary IMTAC™ to identify targets and small molecule drug candidates for Takeda to develop into therapeutic, with over $500 million potential milestone payments plus royalties
- Sichuan Kelun in its licensing and collaboration transaction with Merck for seven pre-clinical ADC programs for $175 million upfront and potential up to $9.3 billion milestone payments
- Cullinan Pearl, a Cullinan Oncology company, in its strategic collaboration and license agreement with Zai Lab for its EGFR inhibitor, CLN-081, in Greater China, for $20 million upfront and up to $211 million in additional milestone payments
- Kymera Therapeutics in its strategic partnership with Sanofi to advance novel protein degrader therapies, with potential deal value of over $2 billion, plus royalties
- Yumanity Therapeutics in its strategic research collaboration and license agreement with Merck focused on accelerating the development of new treatments for neurodegenerative diseases for $500 million
- Kymera Therapeutics in its strategic collaboration with Vertex to advance small molecule protein degraders against multiple biological targets, with an upfront payment of $70 million to Kymera, including an equity investment, and potential future payments to Kymera in excess of $1 billion
- Scholar Rock in its strategic collaboration with Gilead Sciences, with potential deal value of over $1.5 billion
- ImmuNext in its global licensing and research collaboration in immunology with a major pharmaceutical company, with an upfront payment of $40 million, and potential future payments to ImmuNext in excess of $565 million
- Fresenius Medical Care in its global partnership with Humacyte to commercialize the investigational human acellular vessel HUMACYL
- Moderna Therapeutics in its strategic collaboration with a major pharmaceutical company to advance novel mRNA-based personalized cancer vaccines, with an upfront payment of $200 million, and the expansion of the strategic alliance to include additional shared antigen mRNA cancer vaccines, with an equity investment of $125 million
- Nimbus Therapeutics in its strategic alliance with Celgene Corporation in immunology
- Licensing of intellectual property assets from research institutions
- Human Immunology Biosciences (HI-Bio™) on its acquisition by Biogen for $1.15 billion upfront and up to $650 million in potential milestone payments
- The Special Committee of the Board of Directors of NantKwest in connection with NantKwest’s merger with Immunitybio
- Teva Pharmaceuticals in its sale of its specialty global women’s health business for a combined value of $2.5 billion
- Royalty Pharma in its acquisition of an interest in Ionis Pharmaceuticals’ royalty in Biogen’s SPINRAZA® (nusinersen) and Novartis’ pelacarsen for up to $1.125 billion, including an upfront payment of $500 million and up to $625 million in additional pelacarsen milestone payments
- Royalty Pharma in its acquisition of a royalty interest in Amgen’s olpasiran from Arrowhead Pharmaceuticals (NASDAQ: ARWR) for $250 million cash upfront and up to $160 million in additional payments contingent on the achievement of certain clinical, regulatory, and sales milestones
- Royalty Pharma’s acquisition of a royalty interest in TRELEGY ELLIPTA from Theravance Biopharma, Inc. (Nasdaq: TBPH) and Innoviva, Inc. (Nasdaq: INVA) for $1.31 billion in cash up front and up to $300 million in additional contingent payments
- Royalty Pharma’s purchase of MorphoSys’ rights to receive future royalties on Janssen’s Tremfya in connection with a $2 billion strategic funding partnership as part of MorphoSys’ acquisition of Constellation Pharmaceuticals
- Cerevel Therapeutics in its strategic non-dilutive financing transaction with NovaQuest and Bain Capital to fund the full Phase 3 development program for tavapadon in Parkinson’s disease
- Karyopharm Therapeutics in its $150 million royalty-based funding agreement with HealthCare Royalty Partners
- Esperion Therapeutics in its $200 million royalty-based funding agreement with an investor group led by Oberland Capital
Professional Activities
Sarah is a member of the Boston Bar Association.
While attending law school, Sarah served as Managing Editor of the Boston College Law Review.
Credentials
Education
JD2016
Boston College Law School
(cum laude)
BSMolecular and Cellular Biology2013
Johns Hopkins University
Admissions
Bars
- Massachusetts
- Pennsylvania
Related Content
- Press ReleaseFebruary 25, 2026
Goodwin Guides Candel Therapeutics on $100 Million Public Offering and $100 Millon Royalty Funding Agreement With RTW
- Press ReleaseSeptember 18, 2025
Goodwin Advises Ollin Biosciences in $100 Million Launch and Collaboration with Innovent Biologics to Develop OLN324
- Press ReleaseSeptember 2, 2025
Goodwin Advises Replicate Bioscience in Partnership with Novo Nordisk for up to $550 Million
- Awards and RankingsAugust 21, 2025
The Best Lawyers in America 2026 Honors Goodwin Lawyers Nationwide
- Press ReleaseMarch 20, 2025
Goodwin Advises Dren Bio in Acquisition of Bispecific Myeloid Cell Engager by Sanofi
- Press ReleaseNovember 14, 2024
Goodwin Advises Biotheus in Agreement to be Acquired by BioNTech for $800 Million Upfront and $150 Million in Milestones
- Press ReleaseOctober 2, 2024
Goodwin Advises Curon Biopharmaceutical in Acquisition of CN201 by Merck for $700 Million Upfront Plus up to $600 Million Milestones
- Press ReleaseMay 22, 2024
Human Immunology Biosciences to be Acquired by Biogen For $1.15 Billion Upfront and up to $650 Million in Potential Milestone Payments